OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

President Donald Trump has expressed irritation over Ireland’s role as a major exporter of drugs to the US. Botox users may ...

Some of the country's largest drugmakers could be impacted by President Donald Trump's reciprocal tariffs, announced on ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty ...

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Biotech stocks toppled late Wednesday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...